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Aim: To assess the impact of comorbidities on chronic heart failure (CHF) therapy.
Methods: The IMPROVEMENT-HF survey included 11,062 patients from 100 primary care practices in 14 European countries. The
influence of patient characteristics on drug regimes was assessed with multinomial logistical regression.
Results: Combined drug regimes were given to 48% of CHF patients, consisting of 2.2 drugs on average. Patient characteristics accounted
for 35%, 42% and 10% of the variance in one-, two- and three-drug regimes, respectively. Myocardial infarction (MI), atrial fibrillation (AF),
diabetes, hypertension, and lung disease influenced prescribing most. AF made all combinations containing h-blockers more likely. Thus for
single drug regimes, MI increased the likelihood for non-recommended h-blocker monotherapy (OR 1.3; 95% CI 1.2–1.4), while for
combination therapy recommended regimes were most likely. For both hypertension and diabetes, ACE-inhibitors were the most likely single
drug, while the most likely second drugs were h-blockers in hypertension and digoxin in diabetes.
Conclusions: Patient characteristics have a clear impact on prescribing in European primary care. Up to 56% of drug regimes were rational
taking patient characteristics into account. Situations of insufficient prescribing, such as patients post MI, need to be addressed specifically.
D 2005 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.Keywords: European survey; Chronic heart failure; Comorbidities; Prescribing; Primary care; IMPROVEMENT programme1. Introduction
Chronic heart failure (CHF) is a common condition with
increasing prevalence in all western countries [1], has a high
morbidity and mortality, and accounts for expenditure of
around 2% of total healthcare budgets [2]. Therefore,
efficient treatment according to the best available evidence
is of major importance, not only for individual patients’
health outcomes but also for health care spending overall.
At present, evidence-based treatment is not widely
implemented in daily practice [3]. This is particularly
evident in primary care [4,5], which is where the majority1388-9842/$ - see front matter D 2005 European Society of Cardiology. Publishe
doi:10.1016/j.ejheart.2005.03.010
* Corresponding author. Tel.: +31 50 363 2820; fax: +31 50 363 2812.
E-mail address: h.sturm@med.umcg.nl (H.B. Sturm).of heart failure patients are treated in Europe. Moreover,
despite internationally available evidence, there are clear
differences in prescribing between countries both for
inpatient care [6] as well as in primary care [7].
Usually, quality of prescribing is evaluated using a two-
dimensional approach, relating a diagnosis to the use of an
individual drug. In CHF this equates to the overall use of
ACE-inhibitors or h-blockers [6,8]. However, CHF often
requires complex poly-drug regimes. CHF patients fre-
quently have multiple comorbidities, which require over-
lapping therapies. Therefore, patient characteristics are a
very important factor when assessing the quality of
prescribing for heart failure.
The aim of this study in European primary care was to
determine the impact of patient characteristics and comor-t Failure 8 (2006) 31 – 37d by Elsevier B.V. All rights reserved.
Table 2
Prevalence of patient characteristics (determinants for drug regimes) per
H.B. Sturm et al. / The European Journal of Heart Failure 8 (2006) 31–3732bidities on CHF management, and to identify areas of











Sex (M) 56 54 53
Severity (NYHA 3/4) 34 45 58
Goal (relief) 9 9 13
Goal (progress) 61 63 58
Echo (abnormal) 61 73 78
Creatinine (abnormal) 16 18 22
MI 35 36 30
AF 15 25 41
Hypertension 44 54 50
Diabetes 16 20 22
Lung disease 23 24 27
Stroke 7 8 8
Peripheral vascular disease 16 17 212. Methods
2.1. Study population
The data used in this study was derived from the
IMPROVEMENT-HF program, which was undertaken to
evaluate and assess management of CHF [7] in primary care
in Europe. The study was an initiative of the working group
on HF of the European Society of Cardiology (ESC).
Fourteen European countries participated in the survey, each
country had 10 regional centers which randomly selected
approximately 10 primary care physicians to participate in
the survey. The physicians each identified nine patients with
a diagnosis of CHF and/or a history of MI during a 2-month
period in 1999. This created a study population consisting of
11,062 patients. Data for each patient, including relevant
concomitant diseases, diagnostic procedures and pharma-
ceutical treatment was collected by professional health care
workers using patient records. The study design has been
described in detail elsewhere [9].
2.2. Drug regimes
Prescribing patterns were assessed based on drug
regimes rather than on individual drugs. Drug regimesTable 1
Prevalence of drug regimes










Diuretic monotherapy 604 (5.5)
No drug 620 (5.6)














Total patients (11,062) 10,213 (92.3) 849 (7.7)b
Regimes are grouped according to the number of drug classes used,
reflecting treatment intensity.
Regimes <2% were not included in analysis.
a Each regime can contain diuretics.
b Includes also not mentioned combinations.were grouped in levels of comparable treatment intensity
to determine the impact of patient characteristics on
prescribing. Finally, prescription patterns were reassessed
in relation to evidence and recommendations taking the
significant patient characteristics into account.
Regimes with a prescribing frequency <2% (n <250)
in the total population were excluded from the analysis.
Diuretics were not considered as a separate drug
category, as they may be added or withdrawn at any
stage of disease according to symptoms [10]. Thus all
regimes may include diuretics, except for the drug
regimes ‘‘diuretic monotherapy’’ and ‘‘no treatment’’. A
diuretic was defined as loop-diuretic, thiazide or a
combination of both. ‘‘ACE’’ consisted of either ACE-
inhibitor or AII-antagonist.
Three levels of treatment intensity were defined for the
drug regimes according to the number of drug groups
prescribed (one, two or three drugs). The influence of
patient characteristics on prescribing was analyzed within
each level separately and against the recommended drug
regime (Table 1).
2.3. Patient characteristics (determinants)
Patient characteristics included comorbidities and
severity of CHF (Table 2). New York Heart Association
(NYHA) classes 1 and 2 were combined into the category
‘‘mild’’ and NYHA 3 and 4 into ‘‘severe’’. The six
therapeutic goals in the questionnaire were combined to
make three categories: ‘‘relief’’ of symptoms, slowing down
‘‘progress’’ of disease and the combination of ‘‘relief and
progress’’. The latter was used as reference.
2.4. Statistical analysis
The influence of patient characteristics (determinants)
on drug regimes in each therapeutic step was first assessed
using univariate logistic regression. Significant determi-
0,0 0,5 1,0 1,5 2,0 2,5 3,0 0,0 0,5 1,0 1,5 2,0 2,5 3,0
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Fig. 1. Determinants for the use of drug regimes (odds ratios, 95% CI). Explained variance includes all patient characteristics in the model including nationality
Bars entirely on the right indicate that patients with this characteristic are significantly less likely to get the recommended drug regime.
H.B. Sturm et al. / The European Journal of Heart Failure 8 (2006) 31–37 33nants ( p <0.10), with the country as a covariate, were
included in the multivariate analysis. A multinomial
logistical model was performed with random effects [11]
for each therapeutic step.
2.5. Prescribing according to evidence and adjustment to
patient characteristics
Prescribing in relation to evidence was evaluated using
four degrees of adherence:
& Adherence 1: crude adherence directly derived from
guideline recommendations before taking comorbid-.ities into account (=reference drug regimes of each
step);
& Adherence 2: comorbidity induced treatment in line with
evidence and recommendations taking comorbidity into
account;
& Adherence 3: comorbidity induced treatment not in line
with evidence;
& Non-adherent: still unexplainable after taking patient
characteristics into account.
Patients whose treatment was not adherent at the first
level (adherence 1) were reassessed according to their
comorbidities, if these made another drug regime signifi-
H.B. Sturm et al. / The European Journal of Heart Failure 8 (2006) 31–3734cantly more likely (conditions resulting in significant
OR>1; Fig. 1).3. Results
Data from 11,062 patients in 14 countries were analyzed.
Baseline characteristics of the study population and descrip-
tive results are described in detail elsewhere [7]. Mean age
was 69.3 (STD 12.4) years, 45% of the patients were female.
Main factors contributing to CHF were: history of myocar-
dial infarction (34%), ischemic heart disease (28%) and
hypertension (48%). Patients on average had 2.1 coexisting
conditions; only 11% of the patients had none.
On average patients received 1.5 (STD 0.8) drugs for
CHF and 2.2 (STD 1.1) drugs if diuretics were included.
51.8% of the patients were treated with a single drug regime
(potentially including diuretics). Two-drug regimes were
given to about a third and three-drug regimes to 7.7% of the
patients (Table 1).
If a one-drug regime was used, ACE-inhibitors were the
most commonly used drug (42.9%), followed by h-blockers
(20.3%) and digoxin (15.4%). If more than one drug was
given, most combinations contained ACE-inhibitors (93.4%
in two-drug; 94.6% in three-drug regimes). More than half
of the combinations did not include h-blockers (66.3%). For
two-drug regimes the combination of ACE-inhibitors and
digoxin (44.3%) was slightly more commonly prescribed
than ACE-inhibitors combined with h-blockers (42.0%).
ACE-inhibitors and h-blockers were more often combined
with digoxin than with spironolactone.
3.1. Determinants of drug treatment
Patient characteristics accounted for 35%, 42% and 10%
of the variation in each treatment intensity level in the
multivariate analysis (Fig. 1).
Age was a determinant in each step of treatment intensity.
Younger patients were more likely to receive no therapy
rather than single drug regimes (except h-blockers). With
each additional year of age, patients had a 3% greater chance
(OR: 1.03, 95% CI 1.02–1.04) of being given digoxin rather
than an ACE-inhibitor as a single drug regime and a 6%
higher chance (OR: 1.06, 95% CI 1.05–1.07) of being given
digoxin combined with an ACE-inhibitor rather than the
recommended h-blocker combined with an ACE-inhibitor.
Age also increased the chance of receiving spironolactone
rather than a h-blocker in combination with an ACE-
inhibitor plus digoxin by 2% (OR 1.02, 95% CI 1.01–1.04).
Sex was only a significant determinant in the first level
where men were 11% more likely (OR: 1.11, 95% CI 1.02–
1.21) to be given h-blockers and women 10% more likely
(OR: 0.90, 95%CI 0.82–0.98) to be given digoxin thanACE.
Patients with an abnormal echocardiogram were more
likely to receive recommended therapy (ACE-inhibitors
over all other single drug therapies and in combination withh-blockers instead of digoxin (OR: 0.83, 95% CI 0.74–
0.93)).
Higher NYHA score increased the likelihood of getting
ACE-inhibitors rather than no treatment in level one (OR:
1.2, 95% CI: 1.05–1.39) and increased the likelihood of
receiving the recommended treatment within level three
(OR: 2.04, 95% CI: 1.47–2.85).
Patients with a history of MI had a higher chance of
getting h-blockers rather than ACE-inhibitors as single drug
regime (OR: 1.32, 95% CI 1.21–1.43) and combinations
with h-blockers in the more complex treatment regimes.
Patients with atrial fibrillation had a 2.4-fold increased
chance (OR: 2.4, 95% CI 2.2–2.7) of being given digoxin
rather than an ACE-inhibitor for single drug regimes, and a
2.6-fold increased chance (OR 2.64 95% CI 2.35–2.97) of
being given digoxin rather than h-blockers combined with
ACE-inhibitors. h-blockers were more likely to be used than
spironolactone as the third drug in combination with
ACE-inhibitors and digoxin for these patients (OR: 1.46,
95% CI 1.06–2.02).
Hypertension or diabetes both increased the odds of
being given an ACE-inhibitor rather than any other single
drug regime. Within two-drug regimes, h-blockers were
more likely to be given along with ACE-inhibitors in
hypertensive patients (OR 0.81, 95% CI 0.74–0.90),
whereas diabetic patients were more likely to be prescribed
digoxin as the second drug (OR 1.21, 95% CI 1.08–1.36).
Lung disease decreased the chance of getting h-blockers
alone or combined with ACE-inhibitors, but it increased the
chance of being given digoxin or diuretic monotherapy
instead of an ACE-inhibitor.
Most of the influence of abnormal creatinine levels seen
in univariate analysis disappeared when correcting for other
patient characteristics, although there was a higher chance in
single drug regimes for h-blockers to be prescribed rather
than ACE-inhibitors.
3.2. Prescribing according to evidence
Prescription patterns were explained better by taking
patient characteristics into account (Table 3). The overall
crude adherence rate (adherence 1) was 45%. Including
comorbidity-induced prescribing still in line with evidence
and recommendation (adherence 2) increased the overall
rate to 56%. An additional 14% of prescriptions could be
explained by patient characteristics; however, these were
usually not in line with evidence (adherence 3). For
example, 567 patients with a history of MI were treated
only with a h-blocker, 267 patients with lung disease were
treated only with digoxin and 194 with diuretics only.4. Discussion
We aimed to assess the impact of patient characteristics
and comorbidities on CHF treatment in European primary
Table 3
Patient characteristic induced treatment in relation to evidence
Drug regimea Adherence
Adherence 1b Adherence 2 Adherence 3 Non-adherent
n n (determinant) n (determinant) n (determinant)
ACE-inhibitor 2463 0 0 0
BB 0 0 567 (MI) 358 (Male, no MI)
Digoxin 0 0 267 (Lung disease) 0
341 (AF)
Diuretic monotherapy 0 0 194 (Lung disease) 42 (Stroke, no lung disease)
No drug 0 0 0 250 (MI)
53 (Creatinine abnormal)
Total one-drug regimes 2463 0 1369 703
ACE+BB 1629 0 0 0
ACE+digoxin 0 718 (AF) 166 (Diabetes; no AF or lung disease) 0
521 (Lung disease)
ACE+spironolactone 0 100 (Lung disease) 0 0
Total two-drug regimes 1629 1339 166 0
ACE+BB+digoxin 475 0 0 0
ACE+digoxin+spironolactone 0 0 0 175 (AF)
Total three-drug regimes 475 0 0 175
Total patients (11,062) 4567 1339 1535 3114
Adherence (ratec) 45% +11% +14%
Patients whose treatment was not adherent at the first level (adherence 1) were reassessed according to their characteristic, if that made the drug regime
significantly more likely (see text).
a Each regime can contain diuretics.
b Adherence 1: reference drug regimes of each step; adherence 2: patient characteristic induced treatment in line with evidence; adherence 3: patient
characteristic induced treatment usually not in line with evidence.
c Corrected for the number of patients in each treatment intensity step.
H.B. Sturm et al. / The European Journal of Heart Failure 8 (2006) 31–37 35care in order to improve the understanding of prescribing
not in line with evidence.
Two factors inherent in CHF management considered of
major importance for the assessment of prescribing quality
are poly-pharmacy and comorbidities [12]. More than 50%
of the patients in this study were treated with combined drug
regimes and 89% had coexisting diagnoses. Thus physicians
not only have to adapt treatment to the individual patient’s
physical and social situation but also need to take competing
therapeutic requirements and drug interactions into account
[3].
Our analysis identified several important issues. Firstly
and most importantly, comorbidities and other patient
characteristics are key factors driving prescribing patterns,
whether these are in line with recommendations or not.
Secondly, under-prescribing of ACE-inhibitors is limited to
single drug regimes. Finally: prescribing in male patients,
with atrial fibrillation or a history of myocardial infarction
has potential for improvement.
The use of combination therapy as a quality indicator
for CHF drug therapy has been suggested [13,14] but is
not often applied. Initial analysis of this dataset had
already indicated the negative impact of age, concomitant
disease and prior hospitalization on the combined use of
ACE-inhibitors and h-blockers [7]. Further to a recently
published analysis of this population [15], our analysis
enables us to predict which drug combinations are mostlikely to be given to specific patient subgroups. For
instance low use of ACE-inhibitors was restricted to single
drug regimes; however, they were almost always included
in more intense treatment regimes. Furthermore it was
shown that the more complex prescription patterns which
were induced by patient characteristics still resulted in
effective therapy, while single drug regimes often resulted
in insufficient treatment. For example, patients with AF
who are treated with digoxin and an ACE-inhibitor are
being treated in line with recommendations, while those
who are only treated with digoxin have to be considered
undertreated.
In primary care, patient demographics are frequently
different to those from patients included in randomized
clinical trials. Our patient population was about 8 years
older and included 20% more women than an average trial
[16]. This is often used as an argument to justify the lower
uptake of evidence-based treatment in primary care. The
influence of age was a significant determinant for treatment,
even after correction for other potentially debilitating
conditions and the therapeutic goal. The trend to a more
‘‘conservative’’ or symptomatic rather than prognostic
treatment (diuretics or digoxin rather than h-blockers) with
increasing age is in agreement with other studies [17,18].
One possible explanation is that older patients with long-
standing CHF are more likely to be treated with established
therapeutic regimes, which are not automatically updated in
H.B. Sturm et al. / The European Journal of Heart Failure 8 (2006) 31–3736response to newer evidence. Furthermore a perceived lack
of benefit [19–21] could contribute to the potential lack of
awareness of newer evidence including broader study
populations [22]. Also, the tendency in single drug regimes
against the use of ACE inhibitors and a preference for
digoxin or diuretics in women and for h-blockers in men
needs attention.
The common comorbidities in patients with CHF are
potential hurdles to the implementation of therapy according
to guideline recommendations [12,20,23]. Accordingly we
found that lung disease, which was present in about 25% of
patients, decreased the odds of h-blocker and single ACE-
inhibitor therapy significantly.
Moreover, the effect of a given comorbidity could be
detected consistently over all treatment levels. Patients with
a history of MI and those with atrial fibrillation were both
more likely to receive a h-blocker or digoxin rather than an
ACE-inhibitor as a single drug treatment. However, when
more intensive treatment was required, ACE-inhibitors were
the most likely second drug in these patients. This finding is
in line with other studies which describe doctors’ reluctance
to disturb the therapeutic status quo [19], and suggests that
physicians tend to add sequentially to an established therapy
(which might even have been started for a different primary
diagnosis).
Overall crude recommended prescribing (adherence 1)
was 45%, which is compatible with common rates of overall
ACE- and h-blocker-use found in the literature [6,8,17].
However, this assessment does not take into account
coexisting patient conditions from everyday practice, which
is a frequent criticism from practicing physicians. Including
patient characteristics in the assessment gave substantially
higher scores, 56% of prescriptions were in accordance with
evidence for specific patients.
On the other hand, although additional 14% of prescrip-
tions were explained by patient characteristics, those treat-
ments often appeared inappropriate and a further 30% of
treatments remained unexplained. These provide a target for
improving prescribing. Patients with a previous myocardial
infarction, who are more likely be given no drug rather than
ACE-inhibitors, are just one example. The fact that older
age per se evoked a trend to more symptomatic therapy is
another.
4.1. Limitations
All definitions in this study were made in an effort to
measure prescribing quality while taking everyday con-
ditions into account. They are all based on a combination of
guideline recommendations, accumulated evidence and
clinical practice [24].
Drug regimes were defined to make comparisons within
levels of similar treatment intensity possible. Therefore
diuretics which are considered symptomatic drugs, and are
not necessary for maintenance therapy were not defined as a
separate drug class. Digoxin in contrast should be con-tinued, once introduced [10], although the prognostic value
of this drug class for a wider population is still under debate
[24].
Adherence rates can only give indications rather than
absolute measurements and depend on the indicators used.
We tried to reflect everyday practice as much as possible in
our assessment.
4.2. Conclusions and implications
Patient characteristics explain up to one third of the
variation in CHF drug treatment in European primary care.
Up to 56% of prescription patterns appeared rational on
the basis of this analysis and therefore prescribing might
be more rational than generally perceived [25]. On the
other hand, specific areas of poor prescribing were
detected. Therapy is strongly influenced by age and
concomitant conditions, which provide relative contra-
indications. Our results provide the opportunity to target
interventions to improve evidence-based prescribing, par-
ticularly in male patients and those with AF or a history of
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